<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647864</url>
  </required_header>
  <id_info>
    <org_study_id>CAvEAT</org_study_id>
    <nct_id>NCT04647864</nct_id>
  </id_info>
  <brief_title>The Coronary AccEss After Tavi Registry - A Multicenter Prospective Registry for the Coronary Access After TAVI</brief_title>
  <acronym>CAvEAT</acronym>
  <official_title>The Coronary AccEss After Tavi Registry - A Multicenter Prospective Registry for the Coronary Access After TAVI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione GISE Onlus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CAvEAT study is a not for profit, international, multicenter study aimed to assess the&#xD;
      feasibility of selective coronary angiography (CA) after Transcatheter Aortic Valve&#xD;
      Implantation (TAVI), to investigate predictors of successful selective cannulation&#xD;
      (anatomical, technical, etc.) and to investigate if there is a significant difference among&#xD;
      different type of transcatheter valves in selective coronary cannulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Successful selective cannulation of both coronary arteries</measure>
    <time_frame>Immediately after TAVI</time_frame>
    <description>Successful selective cannulation of both coronary arteries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful selective cannulation of only left coronary artery</measure>
    <time_frame>Immediately after TAVI</time_frame>
    <description>Successful selective cannulation of only left coronary artery (and no cannulation or sub selective cannulation of the contralateral)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful selective cannulation of only right coronary artery</measure>
    <time_frame>Immediately after TAVI</time_frame>
    <description>Successful selective cannulation of only right coronary artery (and no cannulation or sub selective cannulation of the contralateral)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Edwards Sapien 3 and Edwards Sapien 3 Ultra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Medtronic Corevalve Evolut R and Medtronic Corevalve Evolut PRO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Boston Scientific Acurate neo and Boston Scientific Acurate neo2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>St. Jude Medical Portico</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation</intervention_name>
    <description>Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Transcatheter Aortic Valve Replacement</other_name>
    <other_name>Percutaneous aortic valve replacement (PAVR)</other_name>
    <other_name>Percutaneous aortic valve implantation (PAVI)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a symptomatic aortic valve disease (stenosis or combined stenosis and&#xD;
        regurgitation), who are candidate to TAVI according to local Heart Team evaluation.&#xD;
        Valve-in-valve procedure due to degeneration of a previously implanted surgical bio&#xD;
        prosthesis are also included in this study population.&#xD;
&#xD;
        All consecutive patients who undergo coronary access immediately after TAVI will be&#xD;
        enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic aortic valve disease (stenosis or combined stenosis and regurgitation)&#xD;
             candidate to TAVI according to local Heart Team evaluation, including valve-in-valve&#xD;
             procedure due to degeneration of a previously implanted surgical bioprosthesis, who&#xD;
             undergo coronary access in the same session of TAVI, immediately after transcatheter&#xD;
             valve deployment (the procedures have to be consecutive);&#xD;
&#xD;
          -  Provision of signed informed consent;&#xD;
&#xD;
          -  Age ≥18 Years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic Kidney Disease stage IV-V (without dialytic treatment; otherwise, patients in&#xD;
             dialytic treatment could be included);&#xD;
&#xD;
          -  Current participation in an interventional clinical study;&#xD;
&#xD;
          -  Age &lt; 18 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matteo Martinato, PhD</last_name>
    <phone>+390498275646</phone>
    <email>matteo.martinato@unipd.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedale Università Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

